---
{"dg-publish":true,"permalink":"/jethro-s-working-notes/romosozumab/","dgPassFrontmatter":true}
---


# Romosozumab

Created: November 22, 2022 4:12 PM
Tags: MSS, Medicine, Pharmacology
Updated: November 24, 2022 12:34 PM

## Romosozumab

Romosozumab is a drug used in the [[Jethro’s Working Notes/Treatment of osteoporosis\|Treatment of osteoporosis]].

- ************************************MOA of Romosozumab************************************
    
    Romosozumab is a human monoclonal antobody that binds to sclerostin, thus inhibiting sclerostin.
    
    This results in increased bone formation, and decreased bone resorption, resulting in increased bone density.
    
- ******Clinical use of Romosozumab******
    
    Romosozumab is given as a subcutaneous injection monthly for a year.
    
    It is only used for cases refractory to [[Jethro’s Working Notes/Bisphosphonate\|Bisphosphonate]] or is at a high risk of fracture.
    
- ************************************************************Adverse effects of romosozumab************************************************************
    - Arthralgia, headaches, insomnia and parasthesia
    - Allergic reaction
    - Hypocalcaemia
    - Severe adverse effects include:
        - Osteonecrosis of the jaw, atypical femoral fractures
        - Increased risk of myocardial infarction, stroke or cardiovascular death
            
            Hence, it is contraindicated in those who had a cardiac event in the previous year.